Evaluation of IL-17A expressions in high-grade glial tumors receiving radiotherapy

Basit Öğe Kaydı
dc.authoridÇiğdem Usul Afşar / 0000-0002-3764-7639en_US
dc.authorscopusidÇiğdem Usul Afşar / 56321181300
dc.authorwosidÇiğdem Usul Afşar / C-3436-2015en_US
dc.contributor.authorKaraca, Figen
dc.contributor.authorKeskin, Selda
dc.contributor.authorMenteş, Şükran Sibel
dc.contributor.authorOkten, A. I.
dc.contributor.authorÇavuş, Gülin
dc.contributor.authorArslan, A.
dc.contributor.authorUsul Afşar, Çiğdem
dc.contributor.authorKöksal, Fatih
dc.date.accessioned2022-05-23T08:36:41Z
dc.date.available2022-05-23T08:36:41Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: In this study, we aimed to investigate the interleukin?17A (IL?17A) levels in patients with high-grade glial tumors before receiving radiotherapy, immediately after radiotherapy, and 3 months after radiotherapy. Patients and Methods: A total of 33 patients who applied to Adana City Training and Research Hospital, Department of Radiation Oncology between December 2016 and May 2018 was included in this study. A total of three blood samples was taken from each patient to assess IL?17A levels before and after radiotherapy and 3 months after the completion of radiotherapy. Results: The differences in IL?17A levels between genders were not statistically significant. IL?17A levels progressively decreased after the radiotherapy and 3 months after the radiotherapy as compared to the levels before radiotherapy. However, this was not statistically significant. IL?17A levels in the non?surviving patients were high before and after radiotherapy as compared to the surviving ones, but this was also not statistically significant. Conclusion: As compared to the period before radiotherapy, IL?17A levels tend to decrease in the period of acute and chronic phases of radiotherapy in all patient groups.en_US
dc.identifier.citationKaraca F, Keskin S, Mentes S, Okten AI, Cavus G, Arslan A, Afsar CU, Koksal F. Evaluation of IL-17A expressions in high-grade glial tumors receiving radiotherapy. Niger J Clin Pract. 2022 May;25(5):582-588. doi: 10.4103/njcp.njcp_1408_21. PMID: 35593599.en_US
dc.identifier.doi10.4103/njcp.njcp_1408_21en_US
dc.identifier.endpage588en_US
dc.identifier.issn1119-3077en_US
dc.identifier.issue5en_US
dc.identifier.pmid35593599en_US
dc.identifier.scopus2-s2.0-85130862514en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage582en_US
dc.identifier.urihttp://doi.org/10.4103/njcp.njcp_1408_21
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2711
dc.identifier.volume25en_US
dc.identifier.wosWOS:000805362600005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUsul Afşar, Çiğdem
dc.language.isoenen_US
dc.publisherNJCPONLİNEen_US
dc.relation.ispartofNigerian Journal of Clinical Practiseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectElisaen_US
dc.subjectIL‑17Aen_US
dc.subjectMalignant Gliomaen_US
dc.subjectRadiotherapyen_US
dc.titleEvaluation of IL-17A expressions in high-grade glial tumors receiving radiotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
NigerJClinPract255582-2749598_073815.pdf
Boyut:
734.05 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu